Arana's pilot for arthritis
Wednesday, 26 November, 2008
Arana Therapeutics has sought approval for a small dose regimen study of its lead inflammatory disease candidate ART621 in rheumatoid arthritis.
The study, to be conducted in Sri Lanka and enrolling 20 patients, will compare four different dose regimens in order to optimise the regimen for its international Phase II dose ranging study.
Arana’s acting CEO Dr Steffen Nock said in an ASX statement that the data gathered from the small study will help fine-tune the larger one.
He said data from the company’s study of ART621 in psoriasis was due early next year.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
